Trial Profile
A study assessing COVID-EIG for the treatment for severe hospitalized patients
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 26 Mar 2020
At a glance
- Drugs COVID-2019 immune globulins (Equine) (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 26 Mar 2020 New trial record
- 11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.
Most Recent Events
Trial Overview
Purpose
This study will be evaluating COVID-EIG for the treatment for severe hospitalized patients.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
- Age Group adult
Trial Details
Organisations
- Affiliations Emergent BioSolutions
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I/II
- Location Unknown
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| COVID-2019 immune globulins (Equine)Primary Drug |
-
|
-
|
COVID-EIG
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 26 Mar 2020 | New trial record | New trial record Updated 26 Mar 2020 |
| 11 Mar 2020 | Other trial event | According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020. Updated 26 Mar 2020 |
References
-
Emergent BioSolutions. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease. Media-Rel 2020;.
Media Release -
Emergent BioSolutions. Emergent BioSolutions Reports Financial Results for First Quarter 2020. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG